Skip to main content

Table 2 Baseline participant characteristics

From: Fish oil supplementation in chronic obstructive pulmonary disease: feasibility of conducting a randomised controlled trial

 

Fish oil (n = 6) median (IQR)

Placebo (n = 6) median (IQR)

Age (years)

68.50 (2.50)

70.5 (6.11)

Sex (n)

 Male

3

4

 Female

3

2

Height (cm)

166.80 (12.74)

167.20 (8.22)

Mass (kg)

85.00 (24.98)

82.20 (24.05)

BMI (kg/m2)

30.02 (6.07)

31.84 (6.07)

Smoking status (n)

 Never

0

1

 Ex-smoker

6

5

mMRC score

1.50 (1.00)

1.00 (1.50)

Dyspnoea-12 (at rest)

12 (16)

8 (1.5)

Borg (dyspnoea, at rest)

0.5 (0.25)

0.25 (0.5)

FEV1/FVC

0.59 (0.05)

0.46 (0.02)

FEV1% predicted

72.00 (13.00)

50.00 (18.00)

Number of medications, total

6 (2)

5 (5)

Number COPD medications

2 (1)

3 (1)

Self-reported comorbidities

4 (2)

3 (2)

Charlson comorbidity scorea

3 (1)

4 (2)

RX-Risk-V

11 (5)

14 (12)

  1. aAge adjusted
  2. BMI body mass index, COPD chronic obstructive pulmonary disease, FEV 1 /FVC forced expiratory volume in 1 s/forced vital capacity, FEV 1 % predicted forced expiratory volume in 1 s percent predicted, IQR interquartile range, mMRC modified Medical Research Council, RX-Risk-V validated prescription medication-based comorbidity index